Ibogaine is drawing new interest from the Trump administration. Here’s what to know about the psychedelic | CNN

Psychedelic drugs, once pushed to the fringes of medicine, are gaining serious attention within the Trump administration as potential treatment options for people with certain mental health conditions. And they could be getting closer to receiving approval from the US Food and Drug Administration. President Donald Trump signed an executive order Saturday designed to fast-track both research on and access to these drugs, including a $50 million investment in state governments to study how psychedelics might help people struggling with mental health illnesses. Psychedelics are a powerful a group of drugs that can alter perception and mood and affect numerous cognitive processes. Some scientists, doctors and patients believe they could hold significant benefits for mental health, especially for conditions that haven’t responded well to traditional treatment approaches. But these drugs can also carry risks that shouldn’t be overlooked. There are many types of psychedelics – including LSD, MDMA and psilocybin, the active ingredient in “magic mushrooms” – but the new executive order mentioned only one by name: ibogaine. Trump accelerates research on psychedelic treatments and